InterVenn Stock
InterVenn Biosciences identifies, quantifies, and classifies Glycoproteomic and other PTM signals found in human blood and tissue.
Sign up today and learn more about InterVenn Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About InterVenn Stock
InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. It was founded in 2017 and headquartered in Redwood City, California.
Investors
Amplify Partners
Anzu Partners
Genoa Ventures
Oriza Ventures
True Ventures
Opendoor, Zymergen, Fitbit, Automattic, Handshake, InterVenn, Personal Capital, Madison Reed, Namely, 3D Robotics
Funding History
| December 2018 | $9.4M |
|---|---|
| July 2020 | $33.7M |
| November 2020 | $34.0M |
| August 2021 | $201M |
Management
Scientific Co-Founder
Carolyn Bertozzi
Co-Founder and CEO
Aldo Carrascoso
Scientific Co-Founder
Carlito Lebrilla
SVP of QA, RA and Customer Excellence
Katherine Dalao
General Manager - Malaysia / VP Business Development
Fadzhairi Jabar
Chief Financial Officer
Brian Hogan
COO
Erwin Estigarribia
Country Manager
Axel Kornerup
Board of Directors
Adam D'Augelli
Investor
Sunil Dhaliwal
Board of Directors
Jenny Rooke
Advisor
Ryan Bethencourt
Senior Director of Pre-clinical R&D
Xin Cong
InterVenn Distinguished Scientist
Klaus Lindpaintner
Board Member
David Michael
Chief Medical Officer
Tillman Pearce
Director
Kenan Pandza
CBO
John Leite
Chief Data Officer
Dan Serie
VP, Clinical Development
Kaitlynn Moser
Press
bizjournals - Jun, 21 2023
Peninsula biotech InterVenn terminates South San Francisco lease amid flooded life sciences marketbiospace - Nov, 13 2022
InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forumbiospace - Oct, 26 2022
Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciencesbiospace - Oct, 6 2022
InterVenn Biosciences Co-Founder Carolyn Bertozzi Awarded Nobel Prize in Chemistrybiospace - Aug, 2 2022
InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Studybizjournals - May, 14 2022
Fast-growing biotech company InterVenn snags more space in South San Franciscobiospace - Jan, 25 2022
InterVenn Promotes Klaus Lindpaintner to InterVenn Distinguished Scientist; Appoints Tillman Pearce as Chief Medical Officerbiospace - Jan, 6 2022
InterVenn Biosciences Names Brian Hogan as Chief Financial Officerbiospace - Nov, 12 2021
InterVenn Biosciences to Participate at Two Upcoming Investor Conferences in Novemberfiercebiotech - Aug, 3 2021
InterVenn Biosciences quintuples funding with $201M for AI-powered cancer testsbiospace - Aug, 2 2021
InterVenn, T-knife and Zentara Bolster Missions with New Fundinganzupartners - Jun, 4 2021
InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics Solutionsprweb - Dec, 3 2020
Slone Partners Places John Leite as Chief Business Officer at InterVenn Biosciencesnews - Nov, 10 2020
InterVenn Biosciences Reports Results on Vista™ : a Multi-Indication Liquid Biopsy Research Panel Built on Glycoproteomicsbioworld - Oct, 14 2020
Intervenn Biosciences IDs COVID-19 risk biomarkers using glycoproteomicsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
